Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway

Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), is the only approved TKI that is effective against T315I mutations in patients with chronic myeloid leukemia (CML). Specific activation of Notch signaling in CML cells by ponatinib can be considered as the “on-target effect” on the tumor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med
Autors principals: Madonna, Rosalinda, Pieragostino, Damiana, Cufaro, Maria Concetta, Doria, Vanessa, Del Boccio, Piero, Deidda, Martino, Pierdomenico, Sante Donato, Dessalvi, Christian Cadeddu, De Caterina, Raffaele, Mercuro, Giuseppe
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7141219/
https://ncbi.nlm.nih.gov/pubmed/32197359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9030820
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars